Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S BARTLETT

Showing results (311-320 of 386) with videos related to

Pageof 39
Sort By:
Breast Cancer Research and Treatment|April 2, 2010
COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patientsJohanna G H van Nes, Esther M de Kruijf, Dana Faratian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2012
Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patientsD B Y Fontein, D Houtsma, E T M Hille, et al.
Breast Cancer Research and Treatment|February 5, 2026
Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudyAndréanne Leblanc, Ana-Alicia Beltran-Bless, Gregory R Pond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology studyJohn M S Bartlett, Kenneth J Bloom, Tammy Piper, et al.
Breast Cancer Research and Treatment|January 25, 2015
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysisC C Engels, A Charehbili, C J H van de Velde, et al.
NPJ Breast Cancer|July 9, 2021
Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology studyJohn M S Bartlett, Jane Bayani, Elizabeth Kornaga, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2017
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramMarijn A Vermeulen, Leen Slaets, Fatima Cardoso, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2017
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim TrialPeter S Hall, Alison Smith, Claire Hulme, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2015
Addressing overtreatment of screen detected DCIS; the LORIS trialAdele Francis, Jeremy Thomas, Lesley Fallowfield, et al.
Lancet (London, England)|January 21, 2011
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trialCornelis J H van de Velde, Daniel Rea, Caroline Seynaeve, et al.
Pageof 39

Showing results (311-320 of 386) with videos related to

Sort By:
Pageof 39
Breast Cancer Research and Treatment|April 2, 2010
COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patientsJohanna G H van Nes, Esther M de Kruijf, Dana Faratian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2012
Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patientsD B Y Fontein, D Houtsma, E T M Hille, et al.
Breast Cancer Research and Treatment|February 5, 2026
Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudyAndréanne Leblanc, Ana-Alicia Beltran-Bless, Gregory R Pond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology studyJohn M S Bartlett, Kenneth J Bloom, Tammy Piper, et al.
Breast Cancer Research and Treatment|January 25, 2015
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysisC C Engels, A Charehbili, C J H van de Velde, et al.
NPJ Breast Cancer|July 9, 2021
Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology studyJohn M S Bartlett, Jane Bayani, Elizabeth Kornaga, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2017
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramMarijn A Vermeulen, Leen Slaets, Fatima Cardoso, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2017
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim TrialPeter S Hall, Alison Smith, Claire Hulme, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2015
Addressing overtreatment of screen detected DCIS; the LORIS trialAdele Francis, Jeremy Thomas, Lesley Fallowfield, et al.
Lancet (London, England)|January 21, 2011
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trialCornelis J H van de Velde, Daniel Rea, Caroline Seynaeve, et al.
Pageof 39